JACKSON T. WRIGHT, JR., MD, PHD, FACP, FASH, FAHA is Professor of Medicine and Program Director of the William T Dahms MD Clinical Research Unit at University Hospitals Cleveland Medical Center. He is also Director of the Clinical Hypertension Program in the Division of Nephrology and Hypertension. He received both his MD and Ph.D. (Pharmacology) from the University of Pittsburgh and completed his Internal Medicine residency at the University of Michigan. He is board certified in Internal Medicine and received subspecialty board certification in Clinical Pharmacology. An experienced clinical investigator, Dr. Wright’s primary research interest is in the clinical pharmacology of antihypertensive and cholesterol lowering agents, especially in minority populations. He has published extensively in this area (over 300 articles, book chapters and abstracts) and served on many national and international advisory panels.
Dr. Wright has had a major or leadership role in nearly all of the major clinical outcome trials conducted in black populations over the past two decades. His leadership and participation in National Institutes of Health-funded clinical trials with large minority representation has resulted in significant advancement of the knowledge base for treatment of hypertension and chronic kidney disease. He served as Vice Chair of the Steering Committee for the NIH-sponsored African American Study of Kidney Disease in Hypertensives Trial (AASK) and first authored its primary results paper. In addition, he is Co-I (initially PI) of one of seven clinical center networks to participate in the National Institute of Diabetes and Digestive and Kidney Diseases-sponsored Chronic Renal Insufficiency Cohort (CRIC) Study.
Dr. Wright also served as Chair of the Executive Committee and Vice Chair of the Steering Committee for the largest study of hypertension treatment ever completed, the Antihypertensive and Lipid-Lowering to Prevent Heart Attack Trial (ALLHAT), where he was the lead author on the primary results paper and the papers presenting the results by race. The study defined optimal hypertensive therapeutic regimens to reduce cardiovascular events, pointing out differences in magnitude of response by ethnicity. It also demonstrated the impact of quality clinical trial data derived from diverse cohorts in optimizing treatment in these same populations. He is currently PI of one of the five clinical center networks in the National Heart, Lung, and Blood Institute-sponsored Systolic Blood Pressure Intervention Trial (SPRINT).
He was selected for service on the three latest U.S. national hypertension guideline panels. He co-chaired the treatment section for the previous Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC 7), served on the panel that generated the 2014 U.S. hypertension guideline report, and currently serves on the hypertension guideline panel convened by the American Heart Association and American College of Cardiology.
American Board of Internal Medicine - Internal Medicine
Education & Training
1967, Ohio Wesleyan University
Medical / Professional School(s)
1976, University of Pittsburgh School of Medicine
1978, Internal Medicine - University of Michigan Hospitals and Health Centers
1980, Internal Medicine - University of Michigan Hospitals and Health Centers
Evaluaton and Management of Resistant Hypertension
UH Cleveland Medical Center
Department of Medicine-Hypertension
11100 Euclid Ave
Orthostatic changes in systolic blood pressure among SPRINT participants at baseline.
Townsend RR, Chang TI, Cohen DL, Cushman WC, Evans GW, Glasser SP, Haley WE, Olney C, Oparil S, Del Pinto R, Pisoni R, Taylor AA, Umanath K, Wright JT Jr, Yeboah J, SPRINT Study Research Group
BP Control and Long-Term Risk of ESRD and Mortality.
Ku E, Gassman J, Appel LJ, Smogorzewski M, Sarnak MJ, Glidden DV, Bakris G, Gutiérrez OM, Hebert LA, Ix JH, Lea J, Lipkowitz MS, Norris K, Ploth D, Pogue VA, Rostand SG, Siew ED, Sika M, Tisher CC, Toto R, Wright JT Jr, Wyatt C, Hsu CY
Reducing Health Inequities in the U.S.: Recommendations From the NHLBI's Health Inequities Think Tank Meeting.
Sampson UK, Kaplan RM, Cooper RS, Diez Roux AV, Marks JS, Engelgau MM, Peprah E, Mishoe H, Boulware LE, Felix KL, Califf RM, Flack JM, Cooper LA, Gracia JN, Henderson JA, Davidson KW, Krishnan JA, Lewis TT, Sanchez E, Luban NL, Vaccarino V, Wong WF, Wright JT Jr, Meyers D, Ogedegbe OG, Presley-Cantrell L, Chambers DA, Belis D, Bennett GC, Boyington JE, Creazzo TL, de Jesus JM, Krishnamurti C, Lowden MR, Punturieri A, Shero ST, Young NS, Zou S, Mensah GA
APOL1 renal-risk variants associate with reduced cerebral white matter lesion volume and increased gray matter volume.
Freedman BI, Gadegbeku CA, Bryan RN, Palmer ND, Hicks PJ, Ma L, Rocco MV, Smith SC, Xu J, Whitlow CT, Wagner BC, Langefeld CD, Hawfield AT, Bates JT, Lerner AJ, Raj DS, Sadaghiani MS, Toto RD, Wright JT Jr, Bowden DW, Williamson JD, Sink KM, Maldjian JA, Pajewski NM, Divers J, African American–Diabetes Heart Study MIND (AA-DHS MIND) and Systolic Blood Pressure Intervention Trial (SPRINT) Research Groups
A Randomized Trial of Intensive versus Standard Blood-Pressure Control.
Wright JT Jr, Whelton PK, Reboussin DM
Race/Ethnicity and Cardiovascular Outcomes in Adults With CKD: Findings From the CRIC (Chronic Renal Insufficiency Cohort) and Hispanic CRIC Studies.
Lash JP, Ricardo AC, Roy J, Deo R, Fischer M, Flack J, He J, Keane M, Lora C, Ojo A, Rahman M, Steigerwalt S, Tao K, Wolf M, Wright JT Jr, Go AS, CRIC Study Investigators
Intensive vs Standard Blood Pressure Control and Cardiovascular Disease Outcomes in Adults Aged ≥75 Years: A Randomized Clinical Trial.
Williamson JD, Supiano MA, Applegate WB, Berlowitz DR, Campbell RC, Chertow GM, Fine LJ, Haley WE, Hawfield AT, Ix JH, Kitzman DW, Kostis JB, Krousel-Wood MA, Launer LJ, Oparil S, Rodriguez CJ, Roumie CL, Shorr RI, Sink KM, Wadley VG, Whelton PK, Whittle J, Woolard NF, Wright JT Jr, Pajewski NM, SPRINT Research Group
Chronic kidney disease, cerebral blood flow, and white matter volume in hypertensive adults.
Tamura MK, Pajewski NM, Bryan RN, Weiner DE, Diamond M, Van Buren P, Taylor A, Beddhu S, Rosendorff C, Jahanian H, Zaharchuk G, SPRINT Study Research Group
Genetic African Ancestry and Markers of Mineral Metabolism in CKD.
Gutiérrez OM, Parsa A, Isakova T, Scialla JJ, Chen J, Flack JM, Nessel LC, Gupta J, Bellovich KA, Steigerwalt S, Sondheimer JH, Wright JT Jr, Feldman HI, Kusek JW, Lash JP, Wolf M
Masked Hypertension and Elevated Nighttime Blood Pressure in CKD: Prevalence and Association with Target Organ Damage.
Drawz PE, Alper AB, Anderson AH, Brecklin CS, Charleston J, Chen J, Deo R, Fischer MJ, He J, Hsu CY, Huan Y, Keane MG, Kusek JW, Makos GK, Miller ER 3rd, Soliman EZ, Steigerwalt SP, Taliercio JJ, Townsend RR, Weir MR, Wright JT Jr, Xie D, Rahman M, Chronic Renal Insufficiency Cohort Study Investigators
University Hospitals is committed to transparency in our interactions with industry partners, such as pharmaceutical, biotech, or medical device companies. At UH, we disclose practitioner and their family members’ ownership and intellectual property rights that are or in the process of being commercialized. In addition, we disclose payments to employed practitioners of $5,000 or more from companies with which the practitioners interact as part of their professional activities. These practitioner-industry relationships assist in developing new drugs, devices and therapies and in providing medical education aimed at improving quality of care and enhancing clinical outcomes. At the same time, UH understands that these relationships may create a conflict of interest. In providing this information, UH desires to assist patients in talking with their practitioners about industry relationships and how those relationships may impact their medical care.
UH practitioners seek advance approval for certain new industry relationships. In addition, practitioners report their industry relationships and activities, as well as those of their immediate family members, to the UH Office of Outside Interests annually. We review these reports and implement management plans, as appropriate, to address conflicts of interest that may arise in connection with medical research, clinical care and purchasing decisions.
View UH’s policy (PDF) on practitioner-industry relationships.
As of December 31, 2015, Jackson Wright, MD, PhD disclosed the following Outside Relationships with Industry:
Medtronic, Inc. - Consulting
Takeda Pharmaceuticals - Consulting